Could Agenus Inc. (AGEN) Crash Even More? The Stock Just Made 52 Week Low

June 17, 2018 - By Adrian Mccoy

Agenus Inc. (NASDAQ:AGEN) Logo

Investors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It is positive, as 11 investors sold Agenus Inc. shares while 24 reduced holdings. 20 funds opened positions while 31 raised stakes. 46.47 million shares or 27.93% more from 36.32 million shares in 2017Q4 were reported.
Goldman Sachs reported 307,353 shares. Jacobs Levy Equity Management invested 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 14,535 shares. Citigroup Inc has invested 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). 25,837 were accumulated by Principal Financial Group. Federated Investors Pa holds 2,098 shares or 0% of its portfolio. State Of Wisconsin Investment Board reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). California Pub Employees Retirement Sys reported 127,253 shares. Victory Mngmt Inc reported 3,692 shares. Walleye Trading Ltd Llc accumulated 28,026 shares or 0% of the stock. Tower Cap Ltd Liability Company (Trc) holds 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 6,992 shares. Crestwood Group Ltd Liability Corporation reported 32,928 shares. Ny State Common Retirement Fund reported 0% in Agenus Inc. (NASDAQ:AGEN). Bluemountain Cap Lc reported 44,743 shares stake. 8,800 were reported by Great West Life Assurance Commerce Can.

The stock of Agenus Inc. (NASDAQ:AGEN) hit a new 52-week low and has $2.59 target or 4.00 % below today’s $2.70 share price. The 6 months bearish chart indicates high risk for the $280.80 million company. The 1-year low was reported on Jun, 17 by If the $2.59 price target is reached, the company will be worth $11.23M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 3.57% or $0.1 during the last trading session, reaching $2.7. About 2.18M shares traded or 49.59% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 0.29% since June 17, 2017 and is downtrending. It has underperformed by 12.86% the S&P500.

Analysts await Agenus Inc. (NASDAQ:AGEN) to report earnings on August, 2. They expect $-0.43 earnings per share, down 34.38 % or $0.11 from last year’s $-0.32 per share. After $-0.42 actual earnings per share reported by Agenus Inc. for the previous quarter, Wall Street now forecasts 2.38 % negative EPS growth.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $280.80 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: